Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Pediatric Review
  • Published:

Nonalcoholic fatty liver disease: a challenge for pediatricians

Abstract

Background:

Nonalcoholic fatty liver disease (NAFLD) is the most common cause of pediatric liver disease. Its prevalence is related to the growing epidemic in childhood obesity during the past decades. At present, NAFLD and nonalcoholic steatohepatitis (NASH) are increasingly recognized worldwide. In spite of alarming trend in the epidemiology in pediatric field and growing risk of end stage liver disease, there is no significant advance in its diagnosis and treatment.

Aim:

To provide a detailed review for diagnosis and management of NAFLD and NASH.

Methods:

By using Pubmed to find review articles and relevant research.

Results:

The prevalence ranges from at least 3% in children overall to about 50% in obese children. The noninvasive biomarkers can be used to identify NAFLD/NASH patients. Diagnostic criteria based on biochemical and immunological indicators in the high-risk group of children could prevent about half of cases from receiving an invasive test. The pharmacological and surgical interventions have shown a growing role in pediatric NAFLD. Novel treatment modalities, such as probiotics, have hardly been studied.

Conclusion:

Early diagnosis by using noninvasive screening methods in high-risk groups is the most effective strategy against the NAFLD. The biology of early growth and development, including hepatic metabolism, may hold the key to pediatric NAFLD. Prevention of overweight children and childhood obesity is undoubtedly the best strategy for treating NAFLD.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Brunt EM . Pathology of nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol 2010; 7: 195–203.

    PubMed  Google Scholar 

  2. Zelman S . The liver in obesity. AMA Arch Intern Med 1952; 90: 141–156.

    CAS  PubMed  Google Scholar 

  3. Ludwig J, Viggiano TR, McGill DB, Oh BJ . Nonalcoholic steatohepatitis: Mayo clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980; 55: 434–438.

    CAS  PubMed  Google Scholar 

  4. Moran JR, Ghishan FK, Halter SA, Greene HL . Steatohepatitis in obese children: a cause of chronic liver dysfunction. Am J Gastroenterol 1983; 78: 374–377.

    CAS  PubMed  Google Scholar 

  5. Feldstein AE, Charatcharoenwitthaya P, Treeprasertsuk S, Benson JT, Enders FB, Angulo P . The natural history of non-alcoholic fatty liver disease in children: a follow-up study for up to 20 years. Gut 2009; 58: 1538–1544.

    CAS  PubMed  Google Scholar 

  6. Patton HM, Sirlin C, Behling C, Middleton M, Schwimmer JB, Lavine JE . Pediatric nonalcoholic fatty liver disease: a critical appraisal of current data and implications for future research. J Pediatr Gastroenterol Nutr 2006; 43: 413–427.

    PubMed  Google Scholar 

  7. Oh MK, Winn J, Poordad F . Review article: diagnosis and treatment of non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2008; 28: 503–522.

    CAS  PubMed  Google Scholar 

  8. Schwimmer JB . Definitive diagnosis and assessment of risk for nonalcoholic fatty liver disease in children and adolescents. Semin Liver Dis 2007; 27: 312–318.

    PubMed  Google Scholar 

  9. Schwimmer JB, McGreal N, Deutsch R, Finegold MJ, Lavine JE . Influence of gender, race, and ethnicity on suspected fatty liver in obese adolescents. Pediatrics 2005; 115: e561–e565.

    PubMed  Google Scholar 

  10. Strauss RS, Barlow SE, Dietz WH . Prevalence of abnormal serum aminotransferase values in overweight and obese adolescents. J Pediatr 2000; 136: 727–733.

    CAS  PubMed  Google Scholar 

  11. Park HS, Han JH, Choi KM, Kim SM . Relation between elevated serum alanine aminotransferase and metabolic syndrome in Korean adolescents. Am J Clin Nutr 2005; 82: 1046–1051.

    CAS  PubMed  Google Scholar 

  12. Nobili V, Reale A, Alisi A, Morino G, Trenta I, Pisani M . et al. Elevated serum ALT in children presenting to the emergency unit: relationship with NAFLD. Dig Liver Dis 2009; 41: 749–752.

    CAS  PubMed  Google Scholar 

  13. Franzese A, Vajro P, Argenziano A, Puzziello A, Iannucci MP, Saviano MC et al. Liver involvement in obese children. Ultrasonography and liver enzyme levels at diagnosis and during follow-up in an Italian population. Dig Dis Sci 1997; 42: 1428–1432.

    CAS  PubMed  Google Scholar 

  14. Reinehr T, Toschke AM . Onset of puberty and cardiovascular risk factors in untreated obese children and adolescents: a 1-year follow-up study. Arch Pediatr Adolesc Med 2009; 163: 709–715.

    PubMed  Google Scholar 

  15. Ko JS, Yoon JM, Yang HR, Myung JK, Kim HR, Kang GH et al. Clinical and histological features of nonalcoholic fatty liver disease in children. Dig Dis Sci 2009; 54: 2225–2230.

    PubMed  Google Scholar 

  16. Baldridge AD, Perez-Atayde AR, Graeme-Cook F, Higgins L, Lavine JE . Idiopathic steatohepatitis in childhood: a multicenter retrospective study. J Pediatr 1995; 127: 700–704.

    CAS  PubMed  Google Scholar 

  17. Schwimmer JB, Deutsch R, Kahen T, Lavine JE, Stanley C, Behling C . Prevalence of fatty liver in children and adolescents. Pediatrics 2006; 118: 1388–1393.

    PubMed  Google Scholar 

  18. Kawasaki T, Hashimoto N, Kikuchi T, Takahashi H, Uchiyama M . The relationship between fatty liver and hyperinsulinemia in obese Japanese children. J Pediatr Gastroenterol Nutr 1997; 24: 317–321.

    CAS  PubMed  Google Scholar 

  19. Chan DF, Li AM, Chu WC, Chan MH, Wong EM, Liu EK et al. Hepatic steatosis in obese Chinese children. Int J Obes Relat Metab Disord 2004; 28: 1257–1263.

    CAS  PubMed  Google Scholar 

  20. Guzzaloni G, Grugni G, Minocci A, Moro D, Morabito F . Liver steatosis in juvenile obesity: correlations with lipid profile, hepatic biochemical parameters and glycemic and insulinemic responses to an oral glucose tolerance test. Int J Obes Relat Metab Disord 2000; 24: 772–776.

    CAS  PubMed  Google Scholar 

  21. Tominaga K, Kurata JH, Chen YK, Fujimoto E, Miyagawa S, Abe I et al. Prevalence of fatty liver in Japanese children and relationship to obesity. An epidemiological ultrasonographic survey. Dig Dis Sci 1995; 40: 2002–2009.

    CAS  PubMed  Google Scholar 

  22. Fu CC, Chen MC, Li YM, Liu TT, Wang LY . The risk factors for ultrasound-diagnosed non-alcoholic fatty liver disease among adolescents. Ann Acad Med Singapore 2009; 38: 15–17.

    PubMed  Google Scholar 

  23. Dâmaso AR, do Prado WL, de Piano A, Tock L, Caranti DA, Lofrano MC et al. Relationship between nonalcoholic fatty liver disease prevalence and visceral fat in obese adolescents. Dig Liver Dis 2008; 40: 132–139.

    PubMed  Google Scholar 

  24. Wanless IR, Lentz JS . Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology 1990; 12: 1106–1110. Intern Med. 2002 Feb;41(2):84-90.

    CAS  PubMed  Google Scholar 

  25. Xanthakos S, Miles L, Bucuvalas J, Daniels S, Garcia V, Inge T . Histologic spectrum of nonalcoholic fatty liver disease in morbidly obese adolescents. Clin Gastroenterol Hepatol 2006; 4: 226–232.

    PubMed  Google Scholar 

  26. Roberts EA . Pediatric nonalcoholic fatty liver disease (NAFLD): a ‘growing’problem? J Hepatol 2007; 46: 1133–1142.

    CAS  PubMed  Google Scholar 

  27. Schwimmer JB, Deutsch R, Rauch JB, Behling C, Newbury R, Lavine JE . Obesity, insulin resistance, and other clinicopathological correlates of pediatric nonalcoholic fatty liver disease. J Pediatr 2003; 143: 500–505.

    PubMed  Google Scholar 

  28. Schwimmer JB, Behling C, Newbury R, Deutsch R, Nievergelt C, Schork NJ et al. Histopathology of pediatric nonalcoholic fatty liver disease. Hepatology 2005; 42: 641–649.

    PubMed  Google Scholar 

  29. Fishbein MH, Miner M, Mogren C, Chalekson J . The spectrum of fatty liver in obese children and the relationship of serum aminotransferases to severity of steatosis. J Pediatr Gastroenterol Nutr 2003; 36: 54–61.

    CAS  PubMed  Google Scholar 

  30. Sartorio A, Del Col A, Agosti F, Mazzilli G, Bellentani S, Tiribelli C et al. Predictors of non-alcoholic fatty liver disease in obese children. Eur J Clin Nutr 2007; 61: 877–883.

    CAS  PubMed  Google Scholar 

  31. Ekstedt M, Franzén LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006; 44: 865–873.

    CAS  PubMed  Google Scholar 

  32. Ciba I, Widhalm K . The association between non-alcoholic fatty liver disease and insulin resistance in 20 obese children and adolescents. Acta Paediatr 2007; 96: 109–112.

    PubMed  Google Scholar 

  33. Nobili V, Marcellini M, Devito R, Ciampalini P, Piemonte F, Comparcola D et al. NAFLD in children: a prospective clinical-pathological study and effect of lifestyle advice. Hepatology 2006; 44: 458–465.

    PubMed  Google Scholar 

  34. Petersen KF, Dufour S, Savage DB, Bilz S, Solomon G, Yonemitsu S et al. The role of skeletal muscle insulin resistance in the pathogenesis of the metabolic syndrome. Proc Natl Acad Sci USA 2007; 104: 12587–12594.

    CAS  PubMed  PubMed Central  Google Scholar 

  35. Nobili V, Alisi A, Panera N, Agostoni C . Low birth weight and catch-up-growth associated with metabolic syndrome: a ten year systematic review. Pediatr Endocrinol Rev 2008; 6: 241–247.

    PubMed  Google Scholar 

  36. Roemmich JN, Clark PA, Lusk M, Friel A, Weltman A, Epstein LH . et al. Pubertal alterations in growth and body composition. VI. Pubertal insulin resistance: relation to adiposity, body fat distribution and hormone release. Int J Obes Relat Metab Disord 2002; 26: 701–709.

    CAS  PubMed  Google Scholar 

  37. Sundaram SS, Zeitler P, Nadeau K . The metabolic syndrome and nonalcoholic fatty liver disease in children. Curr Opin Pediatr 2009; 21: 529–535.

    PubMed  PubMed Central  Google Scholar 

  38. Taksali SE, Caprio S, Dziura J, Dufour S, Calí AM, Goodman TR et al. High visceral and low abdominal subcutaneous fat stores in the obese adolescent: a determinant of an adverse metabolic phenotype. Diabetes 2008; 57: 367–371. .

    CAS  PubMed  Google Scholar 

  39. Schwimmer JB, Pardee PE, Lavine JE, Blumkin AK, Cook S . Cardiovascular risk factors and the metabolic syndrome in pediatric nonalcoholic fatty liver disease. Circulation 2008; 118: 277–283.

    CAS  PubMed  PubMed Central  Google Scholar 

  40. Shi HB, Fu JF, Liang L, Wang CL, Zhu JF, Zhou F et al. Prevalence of nonalcoholic fatty liver disease and metabolic syndrome in obese children. Zhonghua Er Ke Za Zhi 2009; 47: 114–118.

    PubMed  Google Scholar 

  41. Arslan N, Büyükgebiz B, Oztürk Y, Cakmakçi H . Fatty liver in obese children: prevalence and correlation with anthropometric measurements and hyperlipidemia. Turk J Pediatr 2005; 47: 23–27.

    PubMed  Google Scholar 

  42. Zivkovic AM, German JB, Sanyal AJ . Comparative review of diets for the metabolic syndrome: implications for nonalcoholic fatty liver disease. Am J Clin Nutr 2007; 86: 285–300.

    CAS  PubMed  Google Scholar 

  43. Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ . Source of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest 2005; 115: 1343–1351.

    CAS  PubMed  PubMed Central  Google Scholar 

  44. Bugianesi E, Gastaldelli A, Vanni E, Gambino R, Cassader M, Baldi S et al. Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms. Diabetologia 2005; 48: 634–642.

    CAS  PubMed  Google Scholar 

  45. Parks EJ . Dietary carbohydrate's effects on lipogenesis and the relationship of lipogenesis to blood insulin and glucose concentrations. Br J Nutr 2002; 87 (Suppl 2): S247–S253.

    CAS  PubMed  Google Scholar 

  46. Reid BN, Ables GP, Otlivanchik OA, Schoiswohl G, Zechner R, Blaner WS et al. Hepatic overexpression of hormone-sensitive lipase and adipose triglyceride lipase promotes fatty acid oxidation, stimulates direct release of free fatty acids, and ameliorates steatosis. J Biol Chem 2008; 283: 13087–13099.

    CAS  PubMed  PubMed Central  Google Scholar 

  47. Sierra-Johnson J, Romero-Corral A, Somers VK, Lopez-Jimenez F, Walldius G, Hamsten A et al. ApoB/apoA-I ratio: an independent predictor of insulin resistance in US non-diabetic subjects. Eur Heart J 2007; 28: 2637–2643.

    CAS  PubMed  Google Scholar 

  48. Kelishadi R, Cook SR, Amra B, Adibi A . Factors associated with insulin resistance and non-alcoholic fatty liver disease among youths. Atherosclerosis 2009; 204: 538–543.

    CAS  PubMed  Google Scholar 

  49. Pessayre D . Role of mitochondria in non-alcoholic fatty liver disease. J Gastroenterol Hepatol 2007; (Suppl 1): S20–S27.

    CAS  PubMed  Google Scholar 

  50. Fromenty B, Robin MA, Igoudjil A, Mansouri A, Pessayre D . ins and outs of mitochondrial dysfunction in NASH. Diabetes Metab 2004; 30: 121–138.

    CAS  PubMed  Google Scholar 

  51. Lalor PF, Faint J, Aarbodem Y, Hubscher SG, Adams DH . role of cytokines and chemokines in the development of steatohepatitis. Semin Liver Dis 2007; 27: 173–193.

    CAS  PubMed  Google Scholar 

  52. Carter-Kent C, Zein NN, Feldstein AE . in the pathogenesis of fatty liver and disease progression to steatohepatitis: implications for treatment. Am J Gastroenterol 2008; 103: 1036–1042.

    CAS  PubMed  Google Scholar 

  53. Cortez-Pinto H, de Moura MC, Day CP . Non-alcoholic steatohepatitis: from cell biology to clinical practice. J Hepatol 2006; 44: 197–208.

    CAS  PubMed  Google Scholar 

  54. Nagata K, Suzuki H, Sakaguchi S . Common pathogenic mechanism in development progression of liver injury caused by non-alcoholic or alcoholic steatohepatitis. J Toxicol Sci 2007; 32: 453–468.

    CAS  PubMed  Google Scholar 

  55. Cheung AT, Wang J, Ree D, Kolls JK, Bryer-Ash M . Tumor necrosis factor-alpha induces hepatic insulin resistance in obese Zucker (fa/fa) rats via interaction of leukocyte antigen-related tyrosine phosphatase with focal adhesion kinase. Diabetes 2000; 49: 810–819.

    CAS  PubMed  Google Scholar 

  56. Marra F, Bertolani C . Adipokines in liver diseases. Hepatology 2009; 50: 957–969.

    CAS  PubMed  Google Scholar 

  57. Cianfarani S, Martinez C, Maiorana A, Scirè G, Spadoni GL, Boemi S . Adiponectin levels are reduced in children born small for gestational age and are inversely related to postnatal catch-up growth. J Clin Endocrinol Metab 2004; 89: 1346–1351.

    CAS  PubMed  Google Scholar 

  58. Louthan MV, Barve S, McClain CJ, Joshi-Barve S . Decreased serum adiponectin: an early event in pediatric nonalcoholic fatty liver disease. J Pediatr 2005; 147: 835–838.

    CAS  PubMed  Google Scholar 

  59. Iacobellis A, Marcellini M, Andriulli A, Perri F, Leandro G, Devito R et al. Non invasive evaluation of liver fibrosis in paediatric patients with nonalcoholic steatohepatitis. World J Gastroenterol 2006; 12: 7821–7825.

    CAS  PubMed  PubMed Central  Google Scholar 

  60. Basciano H, Federico L, Adeli K . Fructose, insulin resistance, and metabolic dyslipidemia. Nutr Metab (Lond) 2005; 2: 5.

    Google Scholar 

  61. Lee O, Bruce WR, Dong Q, Bruce J, Mehta R, O'Brien PJ . Fructose and carbonyl metabolites as endogenous toxins. Chem Biol Interact 2009; 178: 332–339.

    CAS  PubMed  Google Scholar 

  62. Turcotte LP, Fisher JS . Skeletal muscle insulin resistance: roles of fatty acid metabolism and exercise. Phys Ther 2008; 88: 1279–1296.

    PubMed  PubMed Central  Google Scholar 

  63. Willner IR, Waters B, Patil SR, Reuben A, Morelli J, Riely CA . Ninety patients with nonalcoholic steatohepatitis: insulin resistance, familial tendency, and severity of disease. Am J Gastroenterol 2001; 96: 2957–2961.

    CAS  PubMed  Google Scholar 

  64. Stefan M, Nicholls RD . What have rare genetic syndromes taught us about the pathophysiology of the common forms of obesity? Curr Diab Rep 2004; 4: 143–150.

    PubMed  Google Scholar 

  65. Powell EE, Searle J, Mortimer R . Steatohepatitis associated with limb lipodystrophy. Gastroenterology 1989; 97: 1022–1024.

    CAS  PubMed  Google Scholar 

  66. Punjabi NM, Polotsky VY . Disorders of glucose metabolism in sleep apnea. J Appl Physiol 2005; 99: 1998–2007.

    CAS  PubMed  Google Scholar 

  67. Li J, Grigoryev DN, Ye SQ, Thorne L, Schwartz AR . et al. Chronic intermittent hypoxia upregulates genes of lipid biosynthesis in obese mice. J Appl Physiol 2005; 99: 1643–1648.

    CAS  PubMed  Google Scholar 

  68. Tanné F, Gagnadoux F, Chazouillères O, Fleury B, Wendum D, Lasnier E et al. Chronic liver injury during obstructive sleep apnea. Hepatology 2005; 41: 1290–1296.

    PubMed  Google Scholar 

  69. Savransky V, Bevans S, Nanayakkara A, Li J, Smith PL, Torbenson MS et al. Chronic intermittent hypoxia causes hepatitis in a mouse model of diet-induced fatty liver. Am J Physiol Gastrointest Liver Physiol 2007; 293: G871–G877.

    CAS  PubMed  Google Scholar 

  70. Carter-Kent C, Yerian LM, Brunt EM, Angulo P, Kohli R, Ling SC et al. Nonalcoholic steatohepatitis in children: a multicenter clinicopathological study. Hepatology 2009; 50: 1113–1120.

    PubMed  Google Scholar 

  71. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313–1321.

    PubMed  Google Scholar 

  72. Raszeja-Wyszomirska J, Lawniczak M, Marlicz W, Miezyñska-Kurtycz J, Milkiewicz P . Non-alcoholic fatty liver disease--new view. Pol Merkur Lekarski 2008; 24: 568–571.

    CAS  PubMed  Google Scholar 

  73. Quirós-Tejeira RE, Rivera CA, Ziba TT, Mehta N, Smith CW, Butte NF . Risk for nonalcoholic fatty liver disease in Hispanic youth with BMI > or=95th percentile. J Pediatr Gastroenterol Nutr 2007; 44: 228–236.

    PubMed  Google Scholar 

  74. Ong JP, Elariny H, Collantes R, Younoszai A, Chandhoke V, Reines HD et al. Predictors of nonalcoholic steatohepatitis and advanced fibrosis in morbidly obese patients. Obes Surg 2005; 15: 310–315.

    PubMed  Google Scholar 

  75. Harrison SA, Oliver D, Arnold HL, Gogia S, Neuschwander-Tetri BA . Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut 2008; 57: 1441–1447.

    CAS  PubMed  Google Scholar 

  76. Shimada M, Hashimoto E, Kaneda H, Noguchi S, Hayashi N . Nonalcoholic steatohepatitis: risk factors for liver fibrosis. Hepatol Res 2002; 24: 429–438.

    PubMed  Google Scholar 

  77. Chrysanthos NV, Papatheodoridis GV, Savvas S, Kafiri G, Petraki K, Manesis EK et al. Aspartate aminotransferase to platelet ratio index for fibrosis evaluation in chronic viral hepatitis. Eur J Gastroenterol Hepatol 2006; 18: 389–396.

    CAS  PubMed  Google Scholar 

  78. Abdo AA, Al Swat K, Azzam N, Ahmed S, Al Faleh F . of three noninvasive laboratory variables to predict significant fibrosis and cirrhosis in patients with chronic hepatitis C in Saudi Arabia. Ann Saudi Med 2007; 27: 89–93.

    PubMed  PubMed Central  Google Scholar 

  79. Keskin M, Kurtoglu S, Kendirci M, Atabek ME, Yazici C . Homeostasis model assessment is more reliable than the fasting glucose/insulin ratio and quantitative insulin sensitivity check index for assessing insulin resistance among obese children and adolescents. Pediatrics 2005; 115: e500–e503.

    PubMed  Google Scholar 

  80. Yoo J, Lee S, Kim K, Yoo S, Sung E, Yim J . Relationship between insulin resistance and serum alanine aminotransferase as a surrogate of NAFLD (nonalcoholic fatty liver disease) in obese Korean children. Diabetes Res Clin Pract 2008; 81: 321–326.

    CAS  PubMed  Google Scholar 

  81. D'Adamo E, Impicciatore M, Capanna R, Loredana Marcovecchio M, Masuccio FG et al. Liver steatosis in obese prepubertal children: a possible role of insulin resistance. Obesity (Silver Spring) 2008; 16: 677–683.

    CAS  Google Scholar 

  82. Yoneda M, Mawatari H, Fujita K, Iida H, Yonemitsu K, Kato S et al. High-sensitivity C-reactive protein is an independent clinical feature of nonalcoholic steatohepatitis (NASH) and also of the severity of fibrosis in NASH. J Gastroenterol 2007; 42: 573–582.

    CAS  PubMed  Google Scholar 

  83. Musso G, Gambino R, Biroli G, Carello M, Fagà E, Pacini G et al. Hypoadiponectinemia predicts the severity of hepatic fibrosis and pancreatic Beta-cell dysfunction in nondiabetic nonobese patients with nonalcoholic steatohepatitis. Am J Gastroenterol 2005; 100: 2438–2446.

    CAS  PubMed  Google Scholar 

  84. Bugianesi E, Pagotto U, Manini R, Vanni E, Gastaldelli A, de Iasio R et al. Plasma adiponectin in nonalcoholic fatty liver is related to hepatic insulin resistance and hepatic fat content, not to liver disease severity. J Clin Endocrinol Metab 2005; 90: 3498–3504.

    CAS  PubMed  Google Scholar 

  85. Bookman ID, Pham J, Guindi M, Heathcote EJ . Distinguishing nonalcoholic steatohepatitis from fatty liver: serum-free fatty acids, insulin resistance, and serum lipoproteins. Liver Int 2006; 26: 566–571.

    CAS  PubMed  Google Scholar 

  86. Saadeh S, Younossi ZM, Remer EM, Gramlich T, Ong JP, Hurley M et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 2002; 123: 745–750.

    PubMed  Google Scholar 

  87. Schwenzer NF, Springer F, Schraml C, Stefan N, Machann J, Schick F . Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance. J Hepatol 2009; 51: 433–445.

    PubMed  Google Scholar 

  88. Pacifico L, Celestre M, Anania C, Paolantonio P, Chiesa C, Laghi A . MRI and ultrasound for hepatic fat quantification: relationships to clinical and metabolic characteristics of pediatric nonalcoholic fatty liver disease. Acta Paediatr 2007; 96: 542–547.

    PubMed  Google Scholar 

  89. Hamaguchi M, Kojima T, Itoh Y, Harano Y, Fujii K, Nakajima T et al. The severity of ultrasonographic findings in nonalcoholic fatty liver disease reflects the metabolic syndrome and visceral fat accumulation. Am J Gastroenterol 2007; 102: 2708–2715.

    PubMed  Google Scholar 

  90. Ricci C, Longo R, Gioulis E, Bosco M, Pollesello P, Masutti F et al. Noninvasive in vivo quantitative assessment of fat content in human liver. J Hepatol 1997; 27: 108–113.

    CAS  PubMed  Google Scholar 

  91. Erdogmus B, Tamer A, Buyukkaya R, Yazici B, Buyukkaya A, Korkut E et al. Portal vein hemodynamics in patients with non-alcoholic fatty liver disease. Tohoku J Exp Med 2008; 215: 89–93.

    PubMed  Google Scholar 

  92. Dietrich CF, Lee JH, Gottschalk R, Herrmann G, Sarrazin C, Caspary WF et al. Hepatic and portal vein flow pattern in correlation with intrahepatic fat deposition and liver histology in patients with chronic hepatitis C. AJR Am J Roentgenol 1998; 171: 437–443.

    CAS  PubMed  Google Scholar 

  93. Sagi R, Reif S, Neuman G, Webb M, Phillip M, Shalitin S . Nonalcoholic fatty liver disease in overweight children and adolescents. Acta Paediatr 2007; 96: 1209–1213.

    CAS  PubMed  Google Scholar 

  94. Longo R, Ricci C, Masutti F, Vidimari R, Crocé LS, Bercich L et al. Fatty infiltration of the liver. Quantification by 1H localized magnetic resonance spectroscopy and comparison with computed tomography. Invest Radiol 1993; 28: 297–302.

    CAS  PubMed  Google Scholar 

  95. Park SH, Kim PN, Kim KW, Lee SW, Yoon SE, Park SW et al. Macrovesicular hepatic steatosis in living liver donors: use of CT for quantitative and qualitative assessment. Radiology 2006; 239: 105–112.

    PubMed  Google Scholar 

  96. Tobari M, Hashimoto E, Yatsuji S, Torii N, Shiratori K . Imaging of nonalcoholic steatohepatitis: advantages and pitfalls of ultrasonography and computed tomography. Intern Med 2009; 48: 739–746.

    PubMed  Google Scholar 

  97. Semelka RC, Chung JJ, Hussain SM, Marcos HB, Woosley JT . Chronic hepatitis: correlation of early patchy and late linear enhancement patterns on gadolinium-enhanced MR images with histopathology initial experience. J Magn Reson Imaging 2001; 13: 385–391.

    CAS  PubMed  Google Scholar 

  98. Kanematsu M, Danet MI, Leonardou P, Mastropasqua M, Mosetti MA, Braga L et al. Early heterogeneous enhancement of the liver: magnetic resonance imaging findings and clinical significance. J Magn Reson Imaging 2004; 20: 242–249.

    PubMed  Google Scholar 

  99. Tomita K, Tanimoto A, Irie R, Kikuchi M, Yokoyama H, Teratani T et al. Evaluating the severity of nonalcoholic steatohepatitis with superparamagnetic iron oxide-enhanced magnetic resonance imaging. J Magn Reson Imaging 2008; 28: 1444–1450.

    PubMed  Google Scholar 

  100. Szczepaniak LS, Babcock EE, Schick F, Dobbins RL, Garg A, Burns DK et al. Measurement of intracellular triglyceride stores by H spectroscopy: validation in vivo. Am J Physiol 1999; 276 (5 Pt 1): E977–E989.

    CAS  PubMed  Google Scholar 

  101. Petersen KF, West AB, Reuben A, Rothman DL, Shulman GI . Noninvasive assessment of hepatic triglyceride content in humans with 13C nuclear magnetic resonance spectroscopy. Hepatology 1996; 24: 114–117.

    CAS  PubMed  Google Scholar 

  102. Obara N, Ueno Y, Fukushima K, Nakagome Y, Kakazu E, Kimura O et al. Transient elastography for measurement of liver stiffness measurement can detect early significant hepatic fibrosis in Japanese patients with viral and nonviral liver diseases. J Gastroenterol 2008; 43: 720–728.

    PubMed  Google Scholar 

  103. Wong VW, Vergniol J, Wong GL, Foucher J, Chan HL, Le Bail B et al. Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology 2010; 51: 454–462.

    CAS  PubMed  Google Scholar 

  104. Webb M, Yeshua H, Zelber-Sagi S, Santo E, Brazowski E, Halpern Z et al. Diagnostic value of a computerized hepatorenal index for sonographic quantification of liver steatosis. AJR Am J Roentgenol 2009; 192: 909–914.

    PubMed  Google Scholar 

  105. Oliva MR, Mortele KJ, Segatto E, Glickman JN, Erturk SM, Ros PR et al. Computed tomography features of nonalcoholic steatohepatitis with histopathologic correlation. J Comput Assist Tomogr 2006; 30: 37–43.

    PubMed  Google Scholar 

  106. Pozzato C, Radaelli G, Dall'Asta C, Verduci E, Villa A, Villa C et al. MRI in identifying hepatic steatosis in obese children and relation to ultrasonography and metabolic findings. J Pediatr Gastroenterol Nutr 2008; 47: 493–499.

    PubMed  Google Scholar 

  107. Yokoo T, Bydder M, Hamilton G, Middleton MS, Gamst AC, Wolfson T et al. Nonalcoholic fatty liver disease: diagnostic and fat-grading accuracy of low-flip-angle multiecho gradient-recalled-echo MR imaging at 1.5 T. Radiology 2009; 251: 67–76.

    PubMed  PubMed Central  Google Scholar 

  108. Aguirre DA, Behling CA, Alpert E, Hassanein TI, Sirlin CB . Liver fibrosis: noninvasive diagnosis with double contrast material-enhanced MR imaging. Radiology 2006; 239: 425–437.

    PubMed  Google Scholar 

  109. Wieckowska A, McCullough AJ, Feldstein AE . Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: present and future. Hepatology 2007; 46: 582–589.

    CAS  PubMed  Google Scholar 

  110. Jarrar MH, Baranova A, Collantes R, Ranard B, Stepanova M, Bennett C et al. Adipokines and cytokines in non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2008; 27: 412–421.

    CAS  PubMed  Google Scholar 

  111. Fisher CD, Lickteig AJ, Augustine LM, Ranger-Moore J, Jackson JP, Ferguson SS et al. Hepatic cytochrome P450 enzyme alterations in humans with progressive stages of nonalcoholic fatty liver disease. Drug Metab Dispos 2009; 37: 2087–2094.

    CAS  PubMed  PubMed Central  Google Scholar 

  112. Chalasani N, Deeg MA, Crabb DW . Systemic levels of lipid peroxidation and its metabolic and dietary correlates in patients with nonalcoholic steatohepatitis. Am J Gastroenterol 2004; 99: 1497–1502.

    CAS  PubMed  Google Scholar 

  113. Abiru S, Migita K, Maeda Y, Daikoku M, Ito M, Ohata K . et al. Serum cytokine and soluble cytokine receptor levels in patients with non-alcoholic steatohepatitis. Liver Int 2006; 26: 39–45.

    CAS  PubMed  Google Scholar 

  114. Younossi ZM, Jarrar M, Nugent C, Randhawa M, Afendy M, Stepanova M et al. A novel diagnostic biomarker panel for obesity-related nonalcoholic steatohepatitis (NASH). Obes Surg 2008; 18: 1430–1437.

    PubMed  Google Scholar 

  115. Yoneda M, Iwasaki T, Fujita K, Kirikoshi H, Inamori M, Nozaki Y et al. Hypoadiponectinemia plays a crucial role in the development of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus independent of visceral adipose tissue. Alcohol Clin Exp Res 2007; 31 (1 Suppl): S15–S21.

    PubMed  Google Scholar 

  116. Rosenberg WM, Voelker M, Thiel R, Becka M, Burt A, Schuppan D et al. Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology 2004; 127: 1704–1713.

    PubMed  Google Scholar 

  117. Guha IN, Parkes J, Roderick P, Chattopadhyay D, Cross R, Harris S et al. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers. Hepatology 2008; 47: 455–460.

    PubMed  Google Scholar 

  118. Nobili V, Parkes J, Bottazzo G, Marcellini M, Cross R, Newman D et al. Performance of ELF serum markers in predicting fibrosis stage in pediatric non-alcoholic fatty liver disease. Gastroenterology 2009; 136: 160–167.

    CAS  PubMed  Google Scholar 

  119. Oda E, Watanabe K . C-reactive protein and metabolic syndrome (insulin resistance syndrome), including nonalcoholic steatohepatitis. J Gastroenterol 2008; 43: 312–313.

    PubMed  Google Scholar 

  120. Hui JM, Farrell GC, Kench JG, George J . High sensitivity C-reactive protein values do not reliably predict the severity of histological changes in NAFLD. Hepatology 2004; 39: 1458–1459.

    PubMed  Google Scholar 

  121. Vos MB, Barve S, Joshi-Barve S, Carew JD, Whitington PF, McClain CJ . Cytokeratin 18, a marker of cell death, is increased in children with suspected nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr 2008; 47: 481–485.

    CAS  PubMed  PubMed Central  Google Scholar 

  122. Fu JF, Fang YL, Liang L, Wang CL, Hong F, Dong GP . A rabbit model of pediatric nonalcoholic steatohepatitis: the role of adiponectin. World J Gastroenterol 2009; 15: 912–918.

    CAS  PubMed  PubMed Central  Google Scholar 

  123. Yilmaz Y, Dolar E, Ulukaya E, Akgoz S, Keskin M, Kiyici M, et al. Soluble forms of extracellular cytokeratin 18 may differentiate simple steatosis from nonalcoholic steatohepatitis. World J Gastroenterol 2007; 13: 837–844.

    CAS  PubMed  PubMed Central  Google Scholar 

  124. Palekar NA, Naus R, Larson SP, Ward J, Harrison SA . Clinical model for distinguishing nonalcoholic steatohepatitis from simple steatosis in patients with nonalcoholic fatty liver disease. Liver Int 2006; 26: 151–156.

    PubMed  Google Scholar 

  125. Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007; 45: 846–854.

    CAS  PubMed  Google Scholar 

  126. Calès P, Lainé F, Boursier J, Deugnier Y, Moal V, Oberti F et al. Comparison of blood tests for liver fibrosis specific or not to NAFLD. J Hepatol 2009; 50: 165–173.

    PubMed  Google Scholar 

  127. Nobili V, Alisi A, Vania A, Tiribelli C, Pietrobattista A, Bedogni G . The pediatric NAFLD fibrosis index: a predictor of liver fibrosis in children with non-alcoholic fatty liver disease. BMC Med 2009; 7: 21.

    PubMed  PubMed Central  Google Scholar 

  128. Halfon P, Munteanu M, Poynard T . FibroTest-ActiTest as a non-invasive marker of liver fibrosis. Gastroenterol Clin Biol 2008; 32 (6 Suppl 1): 22–39.

    PubMed  Google Scholar 

  129. Poynard T, Ratziu V, Naveau S, Thabut D, Charlotte F, Messous D . et al. The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis. Comp Hepatol 2005; 4: 10.

    PubMed  PubMed Central  Google Scholar 

  130. Adams LA, Angulo P . Treatment of non-alcoholic fatty liver disease. Postgrad Med J 2006; 82: 315–322.

    CAS  PubMed  PubMed Central  Google Scholar 

  131. Ozkan B, Bereket A, Turan S, Keskin S . Addition of orlistat to conventional treatment in adolescents with severe obesity. Eur J Pediatr 2004; 163: 738–741.

    PubMed  Google Scholar 

  132. Enjoji M, Kotoh K, Kato M, Higuchi N, Kohjima M, Nakashima M et al. Therapeutic effect of ARBs on insulin resistance and liver injury in patients with NAFLD and chronic hepatitis C: a pilot study. Int J Mol Med 2008; 22: 521–527.

    CAS  PubMed  Google Scholar 

  133. Lutchman G, Promrat K, Kleiner DE, Heller T, Ghany MG, Yanovski JA et al. Changes in serum adipokine levels during pioglitazone treatment for nonalcoholic steatohepatitis: relationship to histological improvement. Clin Gastroenterol Hepatol 2006; 4: 1048–1052.

    CAS  PubMed  Google Scholar 

  134. Liew PL, Lee WJ, Lee YC, Wang HH, Wang W, Lin YC . Hepatic histopathology of morbid obesity: concurrence of other forms of chronic liver disease. Obes Surg 2006; 16: 1584–1593.

    PubMed  Google Scholar 

  135. Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001; 108: 1167–1174.

    CAS  PubMed  PubMed Central  Google Scholar 

  136. Morita Y, Ueno T, Sasaki N, Tateishi Y, Nagata E, Kage M et al. Nateglinide is useful for nonalcoholic steatohepatitis (NASH) patients with type 2 diabetes. Hepatogastroenterology 2005; 52: 1338–1343.

    PubMed  Google Scholar 

  137. Rodríguez A, Catalán V, Gómez-Ambrosi J, Frühbeck G . Role of aquaporin-7 in the pathophysiological control of fat accumulation in mice. FEBS Lett 2006; 580: 4771–4776.

    PubMed  Google Scholar 

  138. Ekstedt M, Franzén LE, Mathiesen UL, Holmqvist M, Bodemar G, Kechagias S . Statins in non-alcoholic fatty liver disease and chronically elevated liver enzymes: a histopathological follow-up study. J Hepatol 2007; 47: 135–141.

    CAS  PubMed  Google Scholar 

  139. Merat S, Aduli M, Kazemi R, Sotoudeh M, Sedighi N, Sohrabi M et al. histology changes in nonalcoholic steatohepatitis after one year of treatment with probucol. Dig Dis Sci 2008; 53: 2246–2250.

    CAS  PubMed  Google Scholar 

  140. Nobili V, Manco M, Devito R, Di Ciommo V, Comparcola D, Sartorelli MR et al. Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease: a randomized, controlled trial. Hepatology 2008; 48: 119–128.

    CAS  PubMed  Google Scholar 

  141. Loguercio C, Federico A, Tuccillo C, Terracciano F, D'Auria MV, De Simone C et al. Beneficial effects of a probiotic VSL. J Clin Gastroenterol 2005; 39: 540–543.

    PubMed  Google Scholar 

  142. Lirussi F, Mastropasqua E, Orando S, Orlando R . Probiotics for non-alcoholic fatty liver disease and/or steatohepatitis. Cochrane Database Syst Rev 2007; CD005165.

  143. Mallat A, Teixeira-Clerc F, Deveaux V, Lotersztajn S . Cannabinoid receptors as new targets of antifibrosing strategies during chronic liver diseases. Expert Opin Ther Targets 2007; 11: 403–409.

    PubMed  Google Scholar 

  144. Tock L, Prado WL, Caranti DA, Cristofalo DM, Lederman H, Fisberg M et al. Nonalcoholic fatty liver disease decrease in obese adolescents after multidisciplinary therapy. Eur J Gastroenterol Hepatol 2006; 18: 1241–1245.

    PubMed  Google Scholar 

  145. Vajro P, Mandato C, Franzese A, Ciccimarra E, Lucariello S, Savoia M et al. Vitamin E treatment in pediatric obesity-related liver disease: a randomized study. J Pediatr Gastroenterol Nutr 2004; 38: 48–55.

    CAS  PubMed  Google Scholar 

  146. Abdelmalek MF, Angulo P, Jorgensen RA, Sylvestre PB, Lindor KD . Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study. Am J Gastroenterol 2001; 96: 2711–2717.

    CAS  PubMed  Google Scholar 

  147. Adams LA, Zein CO, Angulo P, Lindor KD . A pilot trial of pentoxifylline in nonalcoholic steatohepatitis. Am J Gastroenterol 2004; 99: 2365–2368.

    CAS  PubMed  Google Scholar 

  148. Riley MR, Bass NM, Rosenthal P, Merriman RB . Underdiagnosis of pediatric obesity and underscreening for fatty liver disease and metabolic syndrome by pediatricians and pediatric subspecialists. J Pediatr 2005; 147: 839–842.

    PubMed  Google Scholar 

  149. Reinehr T, Schmidt C, Toschke AM, Andler W . Lifestyle intervention in obese children with non-alcoholic fatty liver disease: 2-year follow-up study. Arch Dis Child 2009; 94: 437–442.

    CAS  PubMed  Google Scholar 

  150. Nobili V, Manco M, Ciampalini P, Alisi A, Devito R, Bugianesi E . et al. Metformin use in children with nonalcoholic fatty liver disease: an open-label, 24-month, observational pilot study. Clin Ther 2008; 30: 1168–1176.

    CAS  PubMed  Google Scholar 

  151. Wang CL, Liang L, Fu JF, Zou CC, Hong F, Xue JZ et al. Effect of lifestyle intervention on non-alcoholic fatty liver disease in Chinese obese children. World J Gastroenterol 2008; 14: 1598–1602.

    CAS  PubMed  PubMed Central  Google Scholar 

  152. Daubioul CA, Horsmans Y, Lambert P, Danse E, Delzenne NM . Effects of oligofructose on glucose and lipid metabolism in patients with nonalcoholic steatohepatitis: results of a pilot study. Eur J Clin Nutr 2005; 59: 723–726. 618-20.

    CAS  PubMed  Google Scholar 

  153. Kelley DE, Mandarino LJ . Fuel selection in human skeletal muscle in insulin resistance: a reexamination. Diabetes 2000; 49: 677–683.

    CAS  PubMed  Google Scholar 

  154. Houmard JA, Tanner CJ, Slentz CA, Duscha BD, McCartney JS, Kraus WE . Effect of the volume and intensity of exercise training on insulin sensitivity. J Appl Physiol 2004; 96: 101–106.

    CAS  PubMed  Google Scholar 

  155. Khan UI, Collier M . Medical interventions in adolescent obesity. Adolesc Med State Art Rev 2008; 19: 406–420, viii.

    PubMed  Google Scholar 

  156. Atlantis E, Barnes EH, Singh MA . Efficacy of exercise for treating overweight in children and adolescents: a systematic review. Int J Obes (Lond) 2006; 30: 1027–1040.

    CAS  Google Scholar 

  157. Sugerman HJ, Sugerman EL, DeMaria EJ, Kellum JM, Kennedy C, Mowery Y . et al. Bariatric surgery for severely obese adolescents. J Gastrointest Surg 2003; 7: 102–107, discussion 107–108.

    PubMed  Google Scholar 

  158. Nadler EP, Youn HA, Ren CJ, Fielding GA . An update on 73 US obese pediatric patients treated with laparoscopic adjustable gastric banding: comorbidity resolution and compliance data. J Pediatr Surg 2008; 43: 141–146.

    PubMed  Google Scholar 

  159. Clark JM, Alkhuraishi AR, Solga SF, Alli P, Diehl AM, Magnuson TH . Roux-en-Y gastric bypass improves liver histology in patients with non-alcoholic fatty liver disease. Obes Res 2005; 13: 1180–1186.

    PubMed  Google Scholar 

  160. Liu X, Lazenby AJ, Clements RH, Jhala N, Abrams GA . Resolution of nonalcoholic steatohepatits after gastric bypass surgery. Obes Surg 2007; 17: 486–492.

    PubMed  Google Scholar 

  161. TONIC–Treatment of Nonalcoholic Fatty Liver Disease in Children SPGHAN News and Views.. Yigael Finkel, M.D., Ph.D. http://clinicaltrials.gov/ct2/show/NCT00063635.

  162. Nadeau KJ, Ehlers LB, Zeitler PS, Love-Osborne K . Treatment of non-alcoholic fatty liver disease with metformin versus lifestyle intervention in insulin-resistant adolescents. Pediatr Diabetes 2009; 10: 5–13.

    CAS  PubMed  Google Scholar 

  163. Strauss RS . Comparison of serum concentrations of alpha-tocopherol and beta-carotene in a cross-sectional sample of obese and nonobese children (NHANES III) National Health and Nutrition Examination Survey. J Pediatr 1999; 134: 160–165.

    CAS  PubMed  Google Scholar 

  164. Vajro P, Mandato C, Franzese A, Ciccimarra E, Lucariello S, Savoia M et al. Vitamin E treatment in pediatric obesity-related liver disease: a randomized study. J Pediatr Gastroenterol Nutr 2004; 38: 48–55.

    CAS  PubMed  Google Scholar 

  165. Miller 3rd ER, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ, Guallar E . Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med 2005; 142: 37–46.

    CAS  PubMed  Google Scholar 

  166. Lawson ML, Kirk S, Mitchell T, Chen MK, Loux TJ, Daniels SR . et al. One-year outcomes of Roux-en-Y gastric bypass for morbidly obese adolescents: a multicenter study from the Pediatric Bariatric Study Group. J Pediatr Surg 2006; 41: 137–143, discussion 137–143.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to K Widhalm.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Widhalm, K., Ghods, E. Nonalcoholic fatty liver disease: a challenge for pediatricians. Int J Obes 34, 1451–1467 (2010). https://doi.org/10.1038/ijo.2010.185

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ijo.2010.185

Keywords

This article is cited by

Search

Quick links